|
OB/GYN Annual Subject
Index 2001
[ Subject
| Author ]
Adolescence
Chest pain in female adolescents. Aug:20–30
back to top
Alternative medicine
Herbal medicine: focus on phytoestrogens. Jan:36–40
Hot flashes: nonprescription alternatives to ERT/HRT. Mar:50–52
Managing perimenopausal symptoms: an integrative medicine approach
Aug:33–40
Natural progesterone. Apr:43–48
Soy and women's health. Dec:26–37
back to top
Breast diseases
Breast cancer. Oct:16–29
Common benign conditions of the breast. Oct:44–49
back to top
Cancer
Breast cancer. Oct:16–29
Colorectal cancer: does estrogen play a protective role? Nov:45–46
Hereditary gynecologic malignancies. Jun:23–34
The hormone continuum: accrual of women's health benefits. Jan(suppl):10–24
Hormone replacement and breast cancer. Dec(suppl):6–12
Suspicious adnexal masses. May:20–25
Thyroid disorders in the elderly. Apr:15–25
Transitional management: the use of oral contraceptives in perimenopause.
Jan(suppl):4–9
back to top
Cardiovascular disorders
Aldosterone-receptor blocking agents. Oct(suppl):14–18
Cardiovascular implications of hormonal therapy. Dec(suppl):13–19
Chest pain in female adolescents. Aug:20–30
Coronary artery disease prevention in women. Mar:59–65
The hormone continuum: accrual of women's health benefits. Jan(suppl):10–24
Hormone replacement and cardiovascular disease. Oct(suppl):5–9
Progestogens: new approaches. Oct(suppl):19–22
Recent findings in cardiovascular disease. Oct(suppl):3–4
Recurrent nonpuerperal ovarian vein thrombosis. Nov:42–44
Reducing CVD risk through lifestyle modification. Jun(suppl):44–48
The role of potassium. Oct(suppl):10–13
back to top
Continuing Medical Education
(CME)
Aldosterone-receptor blocking agents. Oct(suppl):14–18
Breech presentation. Feb:41–46
Clinician–patient communication. Nov(suppl):8–10
Common benign conditions of the breast. Oct:44–49
Coronary artery disease prevention in women. Mar:59–65
Enhancing normal sexual function. Nov(suppl):15–18
ERT/HRT use in African-American women, part 1: implications for
osteoporosis. Jul:63–67
External genital warts. Nov:50–56
Hormone replacement and cardiovascular disease. Oct(suppl):5–9
Infertility, part 1: genetic causes in females. Aug:55–59
Menstrual migraine. Sep:46–51
Mifepristone. Dec:45–50
Pharmacotherapeutic options. Jul(suppl):10–14
Pre-conception management of women with type I diabetes. May:45–51
Progestogens: new approaches. Oct(suppl):19–22
Recent findings in cardiovascular disease. Oct(suppl):3–4
Reduced-dose oral contraceptives. Sep:24–36
The role of potassium. Oct(suppl):10–13
Sexual dysfunction: current issues. Nov(suppl):4–7
Triplet pregnancy. Apr:54–59
Tubo-ovarian abscess. Jun:43–49
Urinary incontinence: evaluation and nonsurgical management. Jan:41–47
Vaginal atrophy. Nov(suppl):19–22
Women at risk. Jul(suppl):4–9
back to top
Contraception and contraceptives
Access to emergency contraception in the United States. Sep:10–13
Contraception in the perimenopause. Jul:34–42
Emergency contraceptive pills. Mar:15–27
The hormone continuum: accrual of women's health benefits. Jan(suppl):10–24
Mifepristone. Dec:45–50
Recurrent nonpuerperal ovarian vein thrombosis. Nov:42–44
Reduced-dose oral contraceptives. Sep:24–36
Transdermal contraception. Dec:22–25
Transitional management: the use of oral contraceptives in perimenopause.
Jan(suppl):4–9
back to top
Dermatologic disorders
Evaluation of hair loss. May:39–44
back to top
Diabetes
Diabetes management in the new millennium. May:10–12
ERT/HRT in diabetic women. Jan:28–30
Pre-conception management of women with type 1 diabetes. May:45–51
back to top
Dietary interventions
Coronary artery disease prevention in women. Mar:59–65
Hot flashes: nonprescription alternatives to ERT/HRT. Mar:50–52
Reducing CVD risk through lifestyle modification. Jun(suppl):44–48
back to top
Editorials
Access to emergency contraception in the United States. Sep:10–13
Bioterrorism and anthrax anxiety. Dec: 8–10
The business of medicine. Jul:11
A call for clarity in breast care. Oct:11–12
Civility–it's to our advantage. Apr:7–8
Coding and compliance can't be ignored. Jan:9–10
Diabetes management in the new millennium. May:10–12
Evidence-based medicine, revisited. Nov:10
Meeting the needs of the aging female patient. Jun(suppl):9
New medicine, same old problems. Feb:9
New members add dimension to board. Jun:9
The OB/GYN as primary care physician. Mar:9–10
Reflections. Aug:8
back to top
Endocrinologic disorders
Diabetes management in the new millennium. May:10–12
ERT/HRT in diabetic women. Jan:28–30
Evaluation of hair loss. May:39–44
Infertility, part 1: genetic causes in females. Aug:55–59
Infertility, part 2: genetic causes in males. Sep:38–45
Obesity and metabolic changes in aging women. Jun(suppl):39–43
Pre-conception management of women with type I diabetes. May:45–51
Thyroid disorders in the elderly. Apr:15–25
back to top
Exercise
Exercise during pregnancy. Jun:12–18
Medical concerns of endurance athletes. Jul:44–54
Reducing CVD risk through lifestyle modification. Jun(suppl):44–48
back to top
Fetal medicine
Diagnosing the cause of fetal demise. Aug:43–50
Nuchal cord detected on ultrasound. Aug:13–14
Prenatal screening and diagnosis. Jan:21–27
back to top
Gastrointestinal disorders
Chest pain in female adolescents. Aug:20–30
Colorectal cancer: does estrogen play a protective role? Nov:45–46
back to top
Genetics
Hereditary gynecologic malignancies. Jun:23–34
Hormone replacement therapy. Dec(suppl):25–29
Infertility, part 1: genetic causes in females. Aug:55–59
Infertility, part 2: genetic causes in males. Sep:38–45
Inherited bleeding disorders. Feb:20–27
Prenatal screening and diagnosis. Jan:21–27
Women at risk. Jul(suppl):4–9
back to top
Gynecologic disorders
External genital warts. Nov:50–56
Hereditary gynecologic malignancies. Jun:23–34
Hysterosalpingography. Apr:29–40
Infertility, part 1: genetic causes in females. Aug:55–59
Inherited bleeding disorders. Feb:20–27
Natural progesterone. Apr:43–48
Recurrent nonpuerperal ovarian vein thrombosis. Nov:42–44
Soy and women's health. Dec:26–37
Suspicious adnexal masses. May:20–25
Tubo-ovarian abscess. Jun:43–49
Vaginal atrophy. Nov(suppl):19–22
Vulvovaginal candidiasis. March(suppl):4–31
Work-up of bacterial vaginosis. May:29–35
back to top
Hematologic disorders
Inherited bleeding disorders. Feb:20–27
Medical concerns of endurance athletes. Jul:44–54
back to top
Hormones and hormone therapy
Cardiovascular implications of hormonal therapy. Dec(suppl):13–19
Colorectal cancer: does estrogen play a protective role? Nov:45–46
Common benign conditions of the breast. Oct:44–49
Contraception in the perimenopause. Jul:34–42
Coronary artery disease prevention in women. Mar:59–65
Counseling for continuance: improving use of ERT/HRT. Dec:43–44
Emergency contraceptive pills. Mar:15–27
Enhancing normal sexual function. Nov(suppl):15–18
ERT/HRT in diabetic women. Jan:28–30
ERT/HRT use in African-American women, part 1: implications for
osteoporosis. Jul:63–67
Estrogen–androgen therapy. Sep:54–55
Herbal medicine: focus on phytoestrogens. Jan:36–40
The hormone continuum: accrual of women's health benefits. Jan(suppl):10–24
Hormone replacement and breast cancer. Dec(suppl):6–12
Hormone replacement and cardiovascular disease. Oct(suppl):5–9
Hormone replacement therapy. Dec(suppl):25–29
Hot flashes: nonprescription alternatives to ERT/HRT. Mar:50–52
Hot flashes: prescription alternatives to ERT/HRT. Apr:63–64
Managing perimenopausal symptoms: an integrative medicine approach.
Aug:33–40
Menopause transition. Oct:37–38
Menstrual migraine. Sep:46–51
Natural progesterone. Apr:43–48
Pharmacotherapeutic options. Jul(suppl):10–14
Postmenopausal osteoporosis: pharmacologic options for prevention.
Jul:70–71
Preservation of bone density in postmenopausal women. Dec(suppl):20–24
Progestogens: new approaches. Oct(suppl):19–22
Recent findings in cardiovascular disease. Oct(suppl):3–4
Reduced-dose oral contraceptives. Sep:24–36
Sexual dysfunction: current issues. Nov(suppl):4–7
Sleep and menopause. May:57–58
Soy and women's health. Dec:26–37
Surgically induced menopause. Feb:50–51
Transdermal contraception. Dec:22–25
Transitional management: the use of oral contraceptives in perimenopause.
Jan(suppl):4–9
Vaginal atrophy. Nov(suppl):19–22
Women at risk. Jul(suppl):4–9
back to top
Infections
External genital warts. Nov:50–56
HIV and women. Feb:12–18
Tubo-ovarian abscess. Jun:43–49
Vulvovaginal candidiasis. March(suppl):4–31
Work-up of bacterial vaginosis.
May:29–35
back to top
Infertility
Hysterosalpingography. Apr:29–40
Infertility, part 1: genetic causes in females. Aug:55–59
Infertility, part 2: genetic causes in males. Sep:38–45
Natural progesterone. Apr:43–48
back to top
Laparoscopy
Suspicious adnexal masses. May:20–25
back to top
Menopause
Aldosterone-receptor blocking agents. Oct(suppl):14–18
Colorectal cancer: does estrogen play a protective role? Nov:45–46
Confusional states in older women. Jun(suppl):16–25
Contraception in the perimenopause. Jul:34–42
Coronary artery disease prevention in women. Mar:59–65
Counseling for continuance: improving use of ERT/HRT. Dec:43–44
Enhancing normal sexual function. Nov(suppl):15–18
ERT/HRT in diabetic women. Jan:28–30
ERT/HRT use in African-American women, part 1: implications for
osteoporosis. Jul:63–67
Estrogen–androgen therapy. Sep:54–55
Herbal medicine: focus on phytoestrogens. Jan:36–40
The hormone continuum: accrual of women's health benefits. Jan(suppl):10–24
Hormone replacement and cardiovascular disease. Oct(suppl):5–9
Hot flashes: nonprescription alternatives to ERT/HRT. Mar:50–52
Hot flashes: prescription alternatives to ERT/HRT. Apr:63–64
Managing perimenopausal symptoms: an integrative medicine approach.
Aug:33–40
Menopause and mood. Aug:62–63
Menopause and sexual functioning. Jun:35–36
Menopause transition. Oct:37–38
Natural progesterone. Apr:43–48
Obesity and metabolic changes in aging women. Jun(suppl):39–43
Outpatient physical therapy. Jun(suppl):26–31
Overactive bladder in women. Jun(suppl):10–15
Pharmacotherapeutic options. Jul(suppl):10–14
Postmenopausal osteoporosis: pharmacologic options for prevention.
Jul:70–71
Progestogens: new approaches. Oct(suppl):19–22
Recent findings in cardiovascular disease. Oct(suppl):3–4
Reducing CVD risk through lifestyle modification. Jun(suppl):44–48
The role of potassium. Oct(suppl):10–13
Sleep and menopause. May:57–58
Soy and women's health. Dec:26–37
Surgically induced menopause. Feb:50–51
Transitional management: the use of oral contraceptives in perimenopause.
Jan(suppl):4–9
Vaginal atrophy. Nov(suppl):19–22
Women at risk. Jul(suppl):4–9
back to top
Menstrual disorders
Medical concerns of endurance athletes. Jul:44–54
Menopause transition. Oct:37–38
Menstrual migraine. Sep:46–51
Natural progesterone. Apr:43–48
back to top
Musculoskeletal disorders
Chest pain in female adolescents. Aug:20–30
Outpatient physical therapy. Jun(suppl):26–31
back to top
Neurologic disorders
Confusional states in older women. Jun(suppl):16–25
A contrary view: routine magnesium sulfate prophylaxis is unnecessary.
Nov:23–31
Menstrual migraine. Sep:46–51
Seizure prophylaxis: magnesium sulfate advised in pre-eclamptic
parturients. Nov:22–31
back to top
Obesity
Obesity and metabolic changes in aging women. Jun(suppl):39–43
back to top
OB/GYN
The business of medicine. Jul:11 Civility–it's to our advantage.
Apr:7–8
Coding and compliance can't be ignored. Jan:9–10
Deciphering the codes. Jan:31
Evidence-based medicine, revisited. Nov:10
New medicine, same old problems. Feb:9
New members add dimension to board. Jun:9
The OB/GYN as primary care physician. Mar:9–10
Reflections. Aug:8
back to top
Osteoporosis
ERT/HRT use in African-American women, part 1: implications for
osteoporosis. Jul:63–67
The hormone continuum: accrual of women's health benefits. Jan(suppl):10–24
Medical concerns of endurance athletes. Jul:44–54
Obesity and metabolic changes in aging women. Jun(suppl):39–43
Pharmacotherapeutic options. Jul(suppl):10–14
Postmenopausal osteoporosis: pharmacologic options for prevention.
Jul:70–71
Preservation of bone density in postmenopausal women. Dec(suppl):20–24
Transitional management: the use of oral contraceptives in perimenopause.
Jan(suppl):4–9
Women at risk. Jul(suppl):4–9
back to top
Pain
Menstrual migraine. Sep:46–51
back to top
Patient education
Asthma in women. S24:10–13
Bladder disorders. S25:8–11
Body art: the big picture. S30:25–26
Boost your beta-carotene. S28:22
Boost your vitamin C intake. S31:25
Breast cancer screening. S30:4–8
Breathing new life into old allergy care. S26:10–13
Cut calories from fast food. S24:26
Don't be afraid to ask: vaginal infections. S26:29–30
Eating for cancer prevention. S30:22
back to top
Eating healthy and light
Falling into the season. S28:27–28
A heart-healthy and happy new year. S31:23–24
Holiday treats. S30:23–24
A taste of summer. S27:21–22
The epidemic of eating disorders. S30:9–12
Getaways in the golden years. S26:14–15
Hormones and health: living in balance. S25:3–7
Indoor allergies. S24:14–15
Is sex better from a bottle? S30:20–21
Is there an age limit for intimacy? S26:20–21
Is there sex after childbirth? S28:23–24
Keep your family healthy this winter. S31:4–8
Know the signs of preterm labor. S30:27–29
Living well with rheumatoid arthritis. S28:4–7
A look at mifepristone, the "abortion pill." S24:27–28
Menopause matters: a healthy opportunity. S27:17–18
Migraine: you can manage it. S24:4–8
Mistletoe for breast cancer. S27:23–24
Myth or miracle: fad diets exposed. S26:16–19
Non-prescription help for hot flashes. S30:18–19
Overcoming depression. S31:9–16
Overweight kids need our help. S30:13–17
Play it safe this season! S31:19–20
PMS at the next level. S26:22–23
Prescription alternatives for the treatment of hot flashes. S31:17–18
Quick action can minimize stroke damage. S24:16–19
back to top
Quizzes
Eating for cancer prevention. S30:22
Eating your way through menopause. S25:23–24
Nutrition for children. S27:20
Nutrition for the man in your life. S26:32
Nutrition through the ages. S24:22
Relief for urinary tract infections. S28:12–13
Sex education: the early years. S27:19
Sexual dysfunction. S25:20–22
Shoulders, knees, and toes: understanding women's injuries. S26:4–8
Slash your intake of saturated fat. S27:14
Slash your sugar intake. S26:31
SSRIs and sexual dysfunction S31:21–22
Stalking the silent killer: ovarian cancer. S28:8–11
Step into great foot care. S27:15–16
A tailored approach to hormone replacement therapy. S25:15–19
Taking care of the skin you?re in. S27:9–12
Taking control of PMS. S28:17–20
Talking with your health care provider about sexual -dysfunction.
Nov(suppl):13–14
Using hormones in midlife. S28:25–26
Vanquishing varicose veins. S24:20–21
Vitamins, minerals, and bonding. S26:26–28
back to top
What you should know about...
Anxiety. Feb:39–40
Bacterial vaginosis. Dec:41–42
Cholesterol. May:55–56; Jun(suppl):49–50
Emergency contraceptive pills. Mar:47–48
Exercise during pregnancy. Jun:39–40
Genital warts. Nov:47–48
Hirsutism. S26:24–25
Mammography. Oct:33–34
Menstrual migraine. Sep:57–58
Perimenopause. Jul:59–60
Prenatal testing. Aug:53–54
Thyroid disorders. Apr:51–52
Vaginal atrophy. Nov(suppl):11–12
What?s new in contraception? S27:4–8
Your eyes and your hormones. S24:24–25
back to top
Pharmacotherapy
Aldosterone-receptor blocking agents. Oct(suppl):14–18
Antenatal corticosteroids. Dec:12–21
Common benign conditions of the breast. Oct:44–49
Confusional states in older women. Jun(suppl):16–25
A contrary view: routine magnesium sulfate prophylaxis is unnecessary.
Nov:23–31
Enhancing normal sexual function. Nov(suppl):15–18
External genital warts. Nov:50–56
Hot flashes: prescription alternatives to ERT/HRT. Apr:63–64
Menstrual migraine. Sep:46–51
Overactive bladder in women. Jun(suppl):10–15
Pharmacotherapeutic options. Jul(suppl):10–14
Postmenopausal osteoporosis: pharmacologic options for prevention.
Jul:70–71
Psychotropic medications, part 1: use during pregnancy. Jul:21–33
The role of potassium. Oct(suppl):10–13
Seizure prophylaxis: magnesium sulfate advised in pre-eclamptic
parturients. Nov:22–31
Tubo-ovarian abscess. Jun:43–49
Urinary incontinence: evaluation and nonsurgical management. Jan:41–47
Vaginal atrophy. Nov(suppl):19–22
Vulvovaginal candidiasis. March(suppl):4–31
back to top
Pregnancy
Antenatal corticosteroids. Dec:12–21
Breech presentation. Feb:41–46
A contrary view: routine magnesium sulfate prophylaxis is unnecessary.
Nov:23–31
Diagnosing the cause of fetal demise. Aug:43–50
Exercise during pregnancy. Jun:12–18
HIV and women. Feb:12–18
Inherited bleeding disorders. Feb:20–27
Mifepristone. Dec:45–50
Natural progesterone. Apr:43–48
Nuchal cord detected on ultrasound. Aug:13–14
Pre-conception management of women with type I diabetes. May:45–51
Prenatal screening and diagnosis. Jan:21–27
Private or public: umbilical cord blood should be preserved and
stored. Mar:28–44
Psychotropic medications, part 1: use during pregnancy. Jul:21–33
Public UCB banks. Mar:29–44
Seizure prophylaxis: magnesium sulfate advised in pre-eclamptic
parturients. Nov:22–31
Triplet pregnancy. Apr:54–59
back to top
Preventive medicine
Coronary artery disease prevention in women. Mar:59–65
Emergency contraceptive pills. Mar:15–27
ERT/HRT in diabetic women. Jan:28–30
ERT/HRT use in African-American women, part 1: implications for
osteoporosis. Jul:63–67
Postmenopausal osteoporosis: pharmacologic options for prevention.
Jul:70–71
Pre-conception management of women with type I diabetes. May:45–51
back to top
Psychiatric disorders
Anxiety disorders. Feb:31–36
Borderline personality disorder. Nov:32–41
Chest pain in female adolescents. Aug:20–30
Confusional states in older women. Jun(suppl):16–25
Meeting caregivers' health care needs. Jun(suppl):32–38
Menopause and mood. Aug:62–63
Psychotropic medications, part 1: use during pregnancy. Jul:21–33
back to top
Pulmonary disorders
Chest pain in female adolescents. Aug:20–30
back to top
Radiology
Breast cancer. Oct:16–29
Hysterosalpingography. Apr:29–40 S–Z
back to top
Sexuality
Clinician–patient communication. Nov(suppl):8–10
Enhancing normal sexual function. Nov(suppl):15–18
Menopause and sexual functioning. Jun:35–36
Sexual dysfunction: current issues. Nov(suppl):4–7
Surgically induced menopause. Feb:50–51
Vaginal atrophy. Nov(suppl):19–22
back to top
Sexually transmitted diseases
HIV and women. Feb:12–18
back to top
Surgical procedures
Common benign conditions of the breast. Oct:44–49
External genital warts. Nov:50–56
Suspicious adnexal masses. May:20–25
Tubo-ovarian abscess. Jun:43–49
back to top
Ultrasonography
Nuchal cord detected on ultrasound. Aug:13–14
back to top
Urologic disorders
Overactive bladder in women. Jun(suppl):10–15
Urinary incontinence: evaluation and nonsurgical management. Jan:41–47
back to top
|
